Last reviewed · How we verify
NCT03424382
CREATION Health Readmission Risk Assessment Tool
trial in Heart Failure in 1,218 participants. Completed in 26 November 2019.
5 December 2018
Quick facts
| Lead sponsor | AdventHealth |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,218 |
| Start date | 15 May 2017 |
| Primary completion | 5 December 2018 |
| Estimated completion | 26 November 2019 |
| Sites | 1 location across United States |
Conditions studied
- Heart Failure — all drugs for Heart Failure →
- COPD — all drugs for COPD →
- Myocardial Infarction — all drugs for Myocardial Infarction →
- Coronary Artery Bypass Graft — all drugs for Coronary Artery Bypass Graft →
Sponsor
AdventHealth — full company profile →
Who can join
21 and older, any sex, with Heart Failure or COPD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study occurs in two phases. Phase 1 involves initial item development and measurement validation of a new tool for identifying hospitalized patients at high risk for preventable readmission. Primary tasks include item construction and content validation, data collection, analysis, and instrument refinement. Phase 2 involves administering the refined instrument to a new group of patients to determine final item content for the instrument, its factor structure, and its predictive validity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03424382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Heart Failure
Currently open trials in the same condition.
- NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
- NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
- NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
- NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
- NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
Other AdventHealth trials
Trials by the same sponsor.
- NCT07359352 — Surgical Care And Recovery With Laser Evaluation Trial (SCARLET) · NA · not yet recruiting
- NCT07472127 — Professional Readiness Through Emotional Preparedness (PREP) · NA · not yet recruiting
- NCT07357376 — Evaluating Suzetrigine for Pain Control Following TKA · Phase 3 · not yet recruiting
- NCT07298018 — A Pilot Study of RISE for Nurse Managers Retreat · NA · recruiting
- NCT07081542 — Comparative Analysis of Hearing Outcomes: Robotic vs. Manual Insertion of Cochlear Implants · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03424382 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AdventHealth
- Last refreshed: 7 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03424382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing